HF
CDTX

HRT Financial’s Cidara Therapeutics CDTX Stock Holding History

HRT Financial’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-741
Closed -$18K – 2542
2023
Q1 		$18K Buy
+741
New +$21K ﹤0.01% 2189
2022
Q3 		– Sell
-510
Closed -$4K – 2859
2022
Q2 		$4K Buy
+510
New +$6.3K ﹤0.01% 2756
2021
Q4 		– Sell
-3,158
Closed -$141K – 3270
2021
Q3 		$141K Sell
3,158
-1,964
-38% -$74.6K ﹤0.01% 2800
2021
Q2 		$206K Buy
+5,122
New +$217K ﹤0.01% 2369

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

HRT Financial's CDTX Position: Q2 2023 in Review

HRT Financial sold out of Cidara Therapeutics (CDTX) in Q2 2023, closing a stake of 741 shares — an estimated $18K sold.

HRT Financial first reported a position in CDTX in Q2 2021 and held it in 4 quarters. The position peaked at $206K in Q2 2021. 52 funds tracked by Wall St. Rank hold CDTX as of Q2 2023.

  • HRT Financial reported no remaining Cidara Therapeutics position as of Q2 2023 after selling out during the quarter.
  • HRT Financial sold 741 Cidara Therapeutics shares in Q2 2023, an estimated $18K.
  • HRT Financial first reported a position in Cidara Therapeutics in Q2 2021 and held it in 4 quarters.
  • HRT Financial's Cidara Therapeutics position peaked at $206K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.